Dasatinib and Cardiotoxicity - a phase IV clinical study of FDA data

Summary:

Cardiotoxicity is reported as a side effect among people who take Dasatinib (dasatinib), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Tasigna, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Cardiotoxicity when taking Dasatinib. It is created by eHealthMe based on reports of 9,399 people who have side effects when taking Dasatinib from the FDA, and is updated regularly.

What is Dasatinib?

Dasatinib has active ingredients of dasatinib. eHealthMe is studying from 9,407 Dasatinib users. Check the latest studies of Dasatinib.

What is Cardiotoxicity?

Cardiotoxicity (damage to the heart muscle) is found to be associated with 385 drugs and 511 conditions by eHealthMe. Check the latest studies of Cardiotoxicity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

9,399 people reported to have side effects when taking Dasatinib.
Among them, 33 people (0.35%) have Cardiotoxicity.

Among these 33 people:

How long have people been on Dasatinib when they have Cardiotoxicity? *

What is the gender of people who have Cardiotoxicity when taking Dasatinib? *

female: 37.5 %
male: 62.5 %

What is the age of people who have Cardiotoxicity when taking Dasatinib? *

What are other drugs people take besides Dasatinib? *

What are other side effects people have besides Cardiotoxicity? *

Drug Ineffective: 7 people, 21.21%
Cardiac Failure: 6 people, 18.18%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 9.09%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 9.09%
Drug Intolerance (drug sensitivity): 1 person, 3.03%
Anaemia (lack of blood): 1 person, 3.03%
Bone Marrow Failure: 1 person, 3.03%
Congestive Cardiomyopathy (weakening of heart muscle): 1 person, 3.03%
Diastolic Dysfunction: 1 person, 3.03%
Thrombocytopenia (decrease of platelets in blood): 1 person, 3.03%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 17 people, 51.52%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 12 people, 36.36%
Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 2 people, 6.06%
Left Ventricular Dysfunction: 1 person, 3.03%
Bone Marrow Conditioning Regimen: 1 person, 3.03%
Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Dasatinib and have Cardiotoxicity?

- Check whether Cardiotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dasatinib:

Dasatinib (9,407 reports)

Cardiotoxicity treatments and more:

Cardiotoxicity (8,120 reports)

Browse all side effects of Dasatinib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiotoxicity:

Cardiotoxicity (385 drugs)

Browse all the conditions that are associated with Cardiotoxicity:

Cardiotoxicity (511 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dasatinib (the active ingredients of Dasatinib) and Dasatinib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.